Document Type : Review Article
Authors
- Mehdi Ghaderian 1
- Saba Ramezani 2
- Samin Behdad 1
- Mojgan Gharipour 3
- Mehrnoush Dianatkhah 3
- Silva Hovesepian 4
- Negin Salemi 1
1 Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
3 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
4 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
BACKGROUND: Ventricular septal defect (VSD) is a common congenital heart defect that affects many individuals. Transcatheter closure has become a successful treatment method. However, certain devices used for closure can lead to life-threatening complications such as complete heart block. This systematic review aimed to assess the efficacy and safety of Amplatzer duct occluders (ADOs) types I and II for closing perimembranous VSDs (pmVSDs).
METHODS: This review followed the PRISMA 2020 guidelines and searched multiple databases for English articles on pmVSD closure using ADO I/II published up to 2022. Relevant keywords were used and the data were categorized to report the incidence of common complications.
RESULTS: The study, which involved 1,691 patients with primary pmVSD and ages ranging from 6 months to 15 years, found that ADO type I had a high success rate with low rates of complete heart block and other complications. ADO type II had a higher rate of severe complications, particularly complete heart block. The overall estimated success rate for device implantation was 97.3%, with only one procedure-related death. The occurrence of complete heart block was 2.3%, and residual shunts were the most frequent complication (4.8%).
CONCLUSION: The findings of this systematic review provide valuable insights into the use of ADO types I and II for closing pmVSDs. Healthcare professionals should be aware of these findings and closely monitor patients who undergo ADO device closure for pmVSDs. Further research is recommended to determine the specific indications for using each type of Amplatzer device in the relevant population.
Keywords
2. Khoshhal SQ, Al-Mutairi MB, Alnajjar AA, Morsy MM, Salem SS, Al-Muhaya M, et al. Transcatheter device closure of ventricular septal defects in children: a retrospective study at a single cardiac center. Ann Saudi Med. 2020 Sep-Oct;40(5):396-402. https://doi.org/10.5144/0256-4947.2020.396
3. El Shedoudy S, El-Doklah E. Mid-term results of transcatheter closure of ventricular septal defect using Nit-Occlud Lê ventricular septal defect coil, single-center experience. J Saudi Heart Assoc. 2019 Apr;31(2):78-87. https://doi.org/10.1016/j.jsha.2018.11.002
4. Liu S, Chen F, Ding X, Zhao Z, Ke W, Yan Y, et al. Comparison of results and economic analysis of surgical and transcatheter closure of perimembranous ventricular septal defect. Eur J Cardiothorac Surg. 2012 Dec;42(6):e157-62. https://doi.org/10.1093/ejcts/ezs519
5. Yang J, Yang L, Yu S, Liu J, Zuo J, Chen W, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: a randomized controlled trial. J Am Coll Cardiol. 2014 Apr 1;63(12):1159-68. https://doi.org/10.1016/j.jacc.2014.01.008
6. Yang R, Kong XQ, Sheng YH, Zhou L, Xu D, Yong YH, et al. Risk factors and outcomes of post-procedure heart blocks after transcatheter device closure of perimembranous ventricular septal defect. JACC Cardiovasc Interv. 2012 Apr;5(4):422-7. https://doi.org/10.1016/j.jcin.2012.01.015
7. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014 Oct 10;6:359-68. https://doi.org/10.2147/clep.s66677
8. El-Sisi A, Sobhy R, Jaccoub V, Hamza H. Perimembranous Ventricular Septal Defect Device Closure: Choosing Between Amplatzer Duct Occluder I and II. Pediatr Cardiol. 2017 Mar;38(3):596-602. https://doi.org/10.1007/s00246-016-1553-x
9. Pamukcu O, Narin N, Baykan A, Sunkak S, Tasci O, Uzum K. Mid-term results of percutaneous ventricular septal defect closure with Amplatzer Duct Occluder-II in children. Cardiol Young. 2017 Nov;27(9):1726-31. https://doi.org/10.1017/s104795111700107x
10. Vijayalakshmi IB, Narasimhan C, Singh B, Manjunath CN. Treatment of congenital non-ductal shunt lesions with the amplatzer duct occluder II. Catheter Cardiovasc Interv. 2017 May;89(6):E185-93. https://doi.org/10.1002/ccd.25250
11. Knop MT, Litwin L, Szkutnik M, Białkowski J, Galeczka M, Fiszer R. Percutaneous closure of perimembranous and postsurgical ventricular septal defects with Amplatzer Duct Occluder II Additional Sizes in paediatric patients - case series. Postepy Kardiol Interwencyjnej. 2018;14(4):429-32. https://doi.org/10.5114/aic.2018.79874
12. Nguyen HL, Phan QT, Dinh LH, Tran HB, Won H, Thottian JJ, et al. Nit-Occlud Lê VSD coil versus Duct Occluders for percutaneous perimembranous ventricular septal defect closure. Congenit Heart Dis. 2018 Jul;13(4):584-93. https://doi.org/10.1111/chd.12613
13. Zhao LJ, Han B, Zhang JJ, Yi YC, Jiang DD, Lyu JL. Transcatheter closure of congenital perimembranous ventricular septal defect using the Amplatzer duct occluder 2. Cardiol Young. 2018 Mar;28(3):447-453. https://doi.org/10.1017/s1047951117002396
14. Narin N, Pamukcu O, Tuncay A, Baykan A, Sunkak S, Tasci O, et al. Percutaneous Ventricular Septal Defect Closure in Patients Under 1 Year of Age. Pediatr Cardiol. 2018 Jun;39(5):1009-15. https://doi.org/10.1007/s00246-018-1852-5
15. Esmaeili A, Behnke-Hall K, Schrewe R, Schranz D. Percutaneous closure of perimembranous ventricular septal defects utilizing almost ideal Amplatzer Duct Occluder II: Why limitation in sizes? Congenit Heart Dis. 2019 May;14(3):389-95. https://doi.org/10.1111/chd.12731
16. Bosman M, Hoosen E, Degiovanni J. Safety and efficacy of percutaneous closure of perimembranous ventricular septal defects in children: Review of the results at Inkosi Albert Luthuli Central Hospital. SA Heart J. 2019 Mar 1;16(1):14-20. https://doi.org/10.24170/16-1-3407
17. Haddad RN, Daou L, Saliba Z. Device Closure of Perimembranous Ventricular Septal Defect: Choosing Between Amplatzer Occluders. Front Pediatr. 2019 Aug 16;7:300. https://doi.org/10.3389/fped.2019.00300
18. Pillai AA, Rangasamy S, Balasubramonian VR. Transcatheter Closure of Moderate to Large Perimembranous Ventricular Septal Defects in Children Weighing 10 kilograms or less. World J Pediatr Congenit Heart Surg. 2019 May;10(3):278-85. https://doi.org/10.1177/2150135119825562
19. Shrestha M, Promphan W, Layangool T, Roymanee S, Wongwaitaweewong K, Prachasilchai P, et al. Feasibility and 1-year outcome of transcatheter closure of perimembranous ventricular septal defects with different devices. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2019 Jan;93(1):E30–7. https://doi.org/10.1002/ccd.27851
20. Udink Ten Cate FEA, Sobhy R, Kalantre A, Sachdev S, Subramanian A, Koneti NR, et al. Off-label use of duct occluder devices to close hemodynamically significant perimembranous ventricular septal defects: A multicenter experience. Catheter Cardiovasc Interv. 2019 Jan 1;93(1):82-8. https://doi.org/10.1002/ccd.27792
21. Mijangos-Vázquez R, El-Sisi A, Sandoval Jones JP, García-Montes JA, Hernández-Reyes R, Sobhy R, et al. Transcatheter Closure of Perimembranous Ventricular Septal Defects Using Different Generations of Amplatzer Devices: Multicenter Experience. J Interv Cardiol. 2020 Feb 21;2020:8948249. https://doi.org/10.1155/2020/8948249
22. Al Senaidi KS, Al Maskary S, Thomas E, Dimitrov B, Al Farqani A. Percutaneous Closure of Ventricular Septal Defects in 116 Patients: Experience with different devices. Sultan Qaboos Univ Med J. 2020 Nov;20(4):e352–9. https://doi.org/10.18295/squmj.2020.20.04.012
23. Fatema N. Transcatheter closure of ventricular septal defect from retrograde transarterial approach: immediate and long-term outcome. Int J Contemp Pediatr. 2020 Aug 25;7:1830. https://doi.org/10.18203/2349-3291.ijcp20203639
24. Ghosh S, Mukherji A, Chattopadhyay A. Percutaneous closure of moderate to large perimembranous ventricular septal defect in small children using left ventricular mid-cavity approach. Indian Heart J. 2020;72(6):570–5. https://doi.org/10.1016/j.ihj.2020.08.016
25. Jiang D, Zhang J, Fan Y, Han B, Zhao L, Yi Y, et al. The Efficacy and Medium to Long-Term Follow-Up of Transcatheter Retrograde Closure of Perimembranous Ventricular Septal Defects via the Femoral Artery With Amplatzer Duct Occluder II in Children. Front Pediatr. 2021 May 25;9:571407. https://doi.org/10.3389/fped.2021.571407
26. Ghaderian M, Salemi N. Comparison of Long-Term Complications of Using Amplatzer Ductal Occluder and Ventricular Septal Defect Occluder for Transcatheter Ventricular Septal Defect Closure. Heart Views. 2021 Apr-Jun;22(2):102-7. https://doi.org/10.4103/heartviews.heartviews_166_20
27. Wongwaitaweewong K, Promphan W, Roymanee S, Prachasilchai P. Effect of transcatheter closure by AmplatzerTM Duct Occluder II in patients with small ventricular septal defect. Cardiovasc Interv Ther. 2021 Jul;36(3):375-83. https://doi.org/10.1007/s12928-020-00677-z
28. Bergmann M, Germann CP, Nordmeyer J, Peters B, Berger F, Schubert S. Short- and Long-term Outcome After Interventional VSD Closure: A Single-Center Experience in Pediatric and Adult Patients. Pediatr Cardiol. 2021 Jan;42(1):78-88. https://doi.org/10.1007/s00246-020-02456-2
29. Chen TY, Ju YT, Wei YJ, Hsieh ML, Wu JM, Wang JN. Clinical Experience of Transcatheter Closure for Ventricular Septal Defects in Children Weighing under 15 kg. Acta Cardiol Sin. 2021 Nov;37(6):618-24. https://doi.org/10.6515/ACS.202111_37(6).20210726A
30. Liu S, Zhang W, Li J, Wang S, Qian M, Shi J, et al. Transcatheter Closure of Perimembranous and Intracristal Ventricular Septal Defects Using Amplatzer Duct Occluder II in Children. J Interv Cardiol. 2021 Sep 11;2021:4091888. https://doi.org/10.1155/2021/4091888
31. Roy M, Gangopadhyay D, Goyal N, Murthy S, Nandi D, Bandyopadhyay B, et al. Transcatheter closure of ventricular septal defects in children less than 10 kg: experience from a tertiary care referral hospital in Eastern India. Cardiol Young. 2022 Jan;32(1):48-54. https://doi.org/10.1017/s1047951121001578
32. Xiaofei Z, Bin N. Clinical application of the second generation of amplatzer patent ductus arteriosus occluder in the interventional closure of congenital heart disease and case series. World Sci. 2022;6(78):1–13. https://doi.org/10.31435/rsglobal_ws/30122022/7905
33. Jabour Rashid E, Farhan Abusuda A, Ali Hussein A. Early and mid-term results of transcatheter closure of perimembranous ventricular septal defect using Amplatzer Ductal Occluder type 1. Iraq Med J. 2022;6(2):64–7. https://doi.org/10.22317/imj.v6i2.1176
)